# US 2026/0207497 A1 · Lamotrigine Salts, Co-Crystals, and Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0207497 A1
- Document ID: US20260207497A1
- Status: Published application
- Kind: A1
- Application number: 19/570,532
- Filed: 2026-03-18
- Published: 2026-07-23
- Earliest claimed: 2024-09-25
- Assignees: Azurity Pharmaceuticals Ireland Limited
- Applicants: Azurity Pharmaceuticals Ireland Limited
- Inventors: Jordan R. Hunt; Gerold Mosher; Paras P. Jain; Krishna Mohan Lakshmipathula
- Web page: https://patentgrep.com/patent/US20260207497A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07C 57/15: Fumaric acid
- C07D 253/075: Two hetero atoms, in positions 3 and 5
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.

## Claims

### Claim 1

A stable oral suspension comprising lamotrigine salt or a hydrate or a solvate thereof and one or more pharmaceutically acceptable excipient, wherein the amount of lamotrigine salt or a hydrate or a solvate thereof is equivalent to from 1 mg/mL to 50 mg/mL of lamotrigine (free base), and wherein the stable oral suspension is in the form of a liquid.

### Claim 2 (depends on 1)

The stable oral suspension according to claim 1, wherein the amount of lamotrigine salt or a hydrate or a solvate is equivalent to 5 mg/mL of lamotrigine (free base).

### Claim 3 (depends on 1)

The stable oral suspension according to claim 1, wherein the amount of lamotrigine salt or a hydrate or a solvate is equivalent to 25 mg/mL of lamotrigine (free base).

### Claim 4 (depends on 1)

The stable oral suspension according to claim 1, wherein one or more pharmaceutically acceptable excipient is selected from a salting agent; a pH adjuster; a suspending agent; a preservative; a sweetener; an antifoaming agent; an anti-caking agent; and any combination thereof.

### Claim 5 (depends on 1)

The stable oral suspension according to claim 1, wherein the amount of solubilized lamotrigine (free base) in the suspension is less than 1%.

### Claim 6 (depends on 1)

The stable oral suspension according to claim 1, wherein the pH is from 3.0 to 5.0.

### Claim 7 (depends on 1)

The stable oral suspension according to claim 1, wherein the stable oral suspension is stable for six months after being stored at room temperature.

### Claim 8 (depends on 1)

The stable oral suspension according to claim 1, wherein the amount of lamotrigine salt or a hydrate or a solvate is equivalent to 1 mg/mL of lamotrigine (free base).

### Claim 9 (depends on 1)

The stable oral suspension according to claim 1, wherein the lamotrigine salt or a hydrate or a solvate thereof is selected from a lamotrigine hemifumarate anhydrate, a lamotrigine hemifumarate solvate, and a lamotrigine hemifumarate hydrate.

### Claim 10 (depends on 1)

The stable oral suspension according to claim 1, wherein the lamotrigine salt or a hydrate or a solvate thereof is selected from a lamotrigine monofumarate, a lamotrigine hemifumarate, a lamotrigine difumarate, and hydrates and solvates thereof.

### Claim 11 (depends on 10)

The stable oral suspension according to claim 10, wherein the lamotrigine salt or a hydrate or a solvate thereof is lamotrigine hemifumarate anhydrate.

### Claim 12 (depends on 11)

The stable oral suspension according to claim 11, wherein the thermogravimetric analysis (TGA) of lamotrigine hemifumarate anhydrate shows about a 0.55% weight loss when heated from about 23° C. to about 200° C.

### Claim 13 (depends on 11)

The stable oral suspension according to claim 11, wherein the differential scanning calorimetry (DSC) of lamotrigine hemifumarate anhydrate shows a peak at about 272° C. (onset temperature).

### Claim 14 (depends on 1)

The stable oral suspension according to claim 1, wherein amount of 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one (Lamotrigine USP related compound C) is less than about 1 wt % after storage of the stable oral suspension at about 25° C. for 6 months.

### Claim 15 (depends on 1)

The stable oral suspension according to claim 1, wherein amount of 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one (Lamotrigine USP related compound C) is less than about 0.5 wt % after storage of the stable oral suspension at about 25° C. for 6 months.

### Claim 16 (depends on 1)

The stable oral suspension according to claim 1, wherein amount of 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one (Lamotrigine USP related compound C) is less than about 1 wt % after storage of the stable oral suspension at about 40° C. for 6 months.

### Claim 17 (depends on 1)

The stable oral suspension according to claim 1, wherein amount of 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one (Lamotrigine USP related compound C) is less than about 0.5 wt % after storage of the stable oral suspension at about 40° C. for 6 months.

### Claim 18

A stable oral suspension comprising from 1 mg/mL to 50 mg/mL lamotrigine (free base) and a salting agent, wherein the lamotrigine (free base) forms a lamotrigine salt in situ and wherein the stable oral suspension is in the form of a liquid.

### Claim 19 (depends on 18)

The stable oral suspension according to claim 18, wherein the salting agent is fumaric acid and the salt is a fumarate.

### Claim 20 (depends on 18)

The stable oral suspension according to claim 18, wherein the pH is from 3.0 to 5.0.
